Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Final report of a phase II study of ibrutinib and venetoclax in previously untreated Waldenström macroglobulinemia

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAndrew R. BranaganGKGottfried von KeudellSLShirong Liu

Discussion

Loading...

Member takes

Overview

Phase II study shows deep responses with ibrutinib and venetoclax in previously untreated Waldenström macroglobulinemia, suggesting risks of ventricular arrhythmia.

Key Points

  • This study aims to evaluate the safety and efficacy of a fixed-duration treatment combining ibrutinib and venetoclax in patients with Waldenström macroglobulinemia.
  • Conducted as a prospective phase II study in treatment-naïve patients
  • Included 45 patients with tumor lysis syndrome monitoring
  • Utilized Cox regression models to identify predictors of progression-free survival (PFS)
  • 42% of patients achieved a very good partial response (VGPR)
  • Median PFS was 36 months; 4-year OS rate was 91%
  • High serum LDH and low platelet counts were associated with inferior PFS

Cite This Study

Branagan et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d283https://doi.org/10.1182/blood-2025-1794
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Final Report of a Phase <scp>II</scp> Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia2026
  2. 2High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study2025 · 5 citations
  3. 3S2005: A phase II randomized study comparing ibrutinib and rituximab (IR) VS. venetoclax and rituximab (VR) in previously untreated waldenstrom's macroglobulinemia (WM) / lymphoplasmacytic lymphoma (LPL).2025
  4. 4Venetoclax or pirtobrutinib in relapsed/refractory Waldenström macroglobulinemia: Clinical and molecular predictors and sequencing implications2025 · 2 citations
  5. 5BGB-11417-203: An ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia.2024 · 4 citations